Apalutamide and Overall Survival in Prostate Cancer

Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris A. Hadaschik, Julie N. Graff, David Olmos, Paul N. Mainwaring, Ji Youl Lee, Hiroji Uemura, Peter De Porre, Andressa A. Smith, Sabine D. Brookman-May, Susan Li, Ke Zhang, Brendan Rooney, Angela Lopez-Gitlitz, Eric J. Small

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Apalutamide increased overall survival and delayed time to initiation of cytotoxic chemotherapy versus placebo in patients with nonmetastatic castration-resistant prostate cancer. Prior analyses had demonstrated clinically impactful improvement in metastasis-free survival, time to symptomatic progression, and second progression-free survival with apalutamide.

Original languageEnglish (US)
Pages (from-to)150-158
Number of pages9
JournalEuropean Urology
Volume79
Issue number1
DOIs
StatePublished - Jan 2021

Keywords

  • Apalutamide
  • Nonmetastatic castration-resistant prostate cancer
  • Overall survival
  • Subsequent therapy
  • Time to cytotoxic chemotherapy

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Apalutamide and Overall Survival in Prostate Cancer'. Together they form a unique fingerprint.

Cite this